S&P 500   3,370.29 (-0.29%)
DOW   29,232.19 (-0.56%)
QQQ   234.73 (+0.04%)
AAPL   319.00 (-1.83%)
FB   217.80 (+1.69%)
MSFT   187.23 (+1.01%)
GOOGL   1,519.44 (+0.05%)
AMZN   2,155.67 (+0.97%)
CGC   21.94 (-0.86%)
NVDA   296.57 (+2.34%)
BABA   220.52 (+0.41%)
MU   57.75 (-1.28%)
GE   12.75 (-0.62%)
TSLA   858.40 (+7.30%)
AMD   56.89 (+2.86%)
ACB   1.64 (+3.80%)
F   8.05 (-0.62%)
NFLX   387.78 (+1.94%)
BAC   34.27 (-1.66%)
GILD   67.01 (-0.81%)
S&P 500   3,370.29 (-0.29%)
DOW   29,232.19 (-0.56%)
QQQ   234.73 (+0.04%)
AAPL   319.00 (-1.83%)
FB   217.80 (+1.69%)
MSFT   187.23 (+1.01%)
GOOGL   1,519.44 (+0.05%)
AMZN   2,155.67 (+0.97%)
CGC   21.94 (-0.86%)
NVDA   296.57 (+2.34%)
BABA   220.52 (+0.41%)
MU   57.75 (-1.28%)
GE   12.75 (-0.62%)
TSLA   858.40 (+7.30%)
AMD   56.89 (+2.86%)
ACB   1.64 (+3.80%)
F   8.05 (-0.62%)
NFLX   387.78 (+1.94%)
BAC   34.27 (-1.66%)
GILD   67.01 (-0.81%)
S&P 500   3,370.29 (-0.29%)
DOW   29,232.19 (-0.56%)
QQQ   234.73 (+0.04%)
AAPL   319.00 (-1.83%)
FB   217.80 (+1.69%)
MSFT   187.23 (+1.01%)
GOOGL   1,519.44 (+0.05%)
AMZN   2,155.67 (+0.97%)
CGC   21.94 (-0.86%)
NVDA   296.57 (+2.34%)
BABA   220.52 (+0.41%)
MU   57.75 (-1.28%)
GE   12.75 (-0.62%)
TSLA   858.40 (+7.30%)
AMD   56.89 (+2.86%)
ACB   1.64 (+3.80%)
F   8.05 (-0.62%)
NFLX   387.78 (+1.94%)
BAC   34.27 (-1.66%)
GILD   67.01 (-0.81%)
S&P 500   3,370.29 (-0.29%)
DOW   29,232.19 (-0.56%)
QQQ   234.73 (+0.04%)
AAPL   319.00 (-1.83%)
FB   217.80 (+1.69%)
MSFT   187.23 (+1.01%)
GOOGL   1,519.44 (+0.05%)
AMZN   2,155.67 (+0.97%)
CGC   21.94 (-0.86%)
NVDA   296.57 (+2.34%)
BABA   220.52 (+0.41%)
MU   57.75 (-1.28%)
GE   12.75 (-0.62%)
TSLA   858.40 (+7.30%)
AMD   56.89 (+2.86%)
ACB   1.64 (+3.80%)
F   8.05 (-0.62%)
NFLX   387.78 (+1.94%)
BAC   34.27 (-1.66%)
GILD   67.01 (-0.81%)
Log in

NASDAQ:ARWR - Arrowhead Pharmaceuticals Stock Price, Forecast & News

$40.55
-0.72 (-1.74 %)
(As of 02/18/2020 04:00 PM ET)
Today's Range
$39.94
Now: $40.55
$41.22
50-Day Range
$40.43
MA: $50.13
$64.22
52-Week Range
$17.27
Now: $40.55
$73.72
Volume52,879 shs
Average Volume1.79 million shs
Market Capitalization$4.12 billion
P/E Ratio76.51
Dividend YieldN/A
Beta1.95
Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's pipeline include ARO-AAT, a RNA interference (RNAi) therapeutic candidate for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3 to treat hypertriglyceridemia; ARO-ANG3 to reduce production of angiopoietin-like protein 3; ARO-ENaC to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; and ARO-HIF2 for the treatment of clear cell renal cell carcinoma. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ARWR
CUSIPN/A
Phone626-304-3400

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$168.80 million
Cash Flow$0.76 per share
Book Value$2.57 per share

Profitability

Net Income$67.97 million

Miscellaneous

Employees116
Market Cap$4.12 billion
Next Earnings Date5/13/2020 (Estimated)
OptionableOptionable

Receive ARWR News and Ratings via Email

Sign-up to receive the latest news and ratings for ARWR and its competitors with MarketBeat's FREE daily newsletter.


Arrowhead Pharmaceuticals (NASDAQ:ARWR) Frequently Asked Questions

What is Arrowhead Pharmaceuticals' stock symbol?

Arrowhead Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARWR."

How were Arrowhead Pharmaceuticals' earnings last quarter?

Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) announced its quarterly earnings results on Wednesday, February, 5th. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by $0.07. The biotechnology company earned $29.46 million during the quarter, compared to analyst estimates of $36.63 million. Arrowhead Pharmaceuticals had a net margin of 32.56% and a return on equity of 18.21%. View Arrowhead Pharmaceuticals' Earnings History.

When is Arrowhead Pharmaceuticals' next earnings date?

Arrowhead Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, May 13th 2020. View Earnings Estimates for Arrowhead Pharmaceuticals.

What price target have analysts set for ARWR?

9 brokers have issued 12-month target prices for Arrowhead Pharmaceuticals' stock. Their forecasts range from $32.00 to $83.00. On average, they anticipate Arrowhead Pharmaceuticals' share price to reach $64.13 in the next year. This suggests a possible upside of 58.3% from the stock's current price. View Analyst Price Targets for Arrowhead Pharmaceuticals.

What is the consensus analysts' recommendation for Arrowhead Pharmaceuticals?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arrowhead Pharmaceuticals in the last year. There are currently 2 sell ratings, 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Arrowhead Pharmaceuticals.

Has Arrowhead Pharmaceuticals been receiving favorable news coverage?

Press coverage about ARWR stock has been trending neutral this week, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Arrowhead Pharmaceuticals earned a daily sentiment score of 0.3 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 2.0 out of 10, meaning that recent press coverage is very unlikely to have an impact on the company's share price in the near term. View News Stories for Arrowhead Pharmaceuticals.

Are investors shorting Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals saw a decrease in short interest in January. As of January 15th, there was short interest totalling 11,120,000 shares, a decrease of 8.9% from the December 31st total of 12,200,000 shares. Based on an average trading volume of 2,270,000 shares, the short-interest ratio is presently 4.9 days. Currently, 12.0% of the company's stock are sold short. View Arrowhead Pharmaceuticals' Current Options Chain.

Who are some of Arrowhead Pharmaceuticals' key competitors?

What other stocks do shareholders of Arrowhead Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arrowhead Pharmaceuticals investors own include Bellicum Pharmaceuticals (BLCM), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), AbbVie (ABBV), Sarepta Therapeutics (SRPT), Advanced Micro Devices (AMD), salesforce.com (CRM), Bank of America (BAC) and Bristol-Myers Squibb (BMY).

Who are Arrowhead Pharmaceuticals' key executives?

Arrowhead Pharmaceuticals' management team includes the folowing people:
  • Dr. Christopher R. Anzalone, CEO, Pres & Director (Age 50)
  • Mr. Kenneth A. Myszkowski, Chief Financial Officer (Age 53)
  • Dr. Bruce D. Given, Chief Operating Officer (Age 65)
  • Mr. Patrick O'Brien, Gen. Counsel (Age 55)
  • Dr. Mark M. Davis, Founder and Founder & Director of Insert Therapeutics Inc & Calando

Who are Arrowhead Pharmaceuticals' major shareholders?

Arrowhead Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include State Street Corp (4.06%), FMR LLC (1.85%), Fiera Capital Corp (1.34%), Bank of New York Mellon Corp (1.05%), Goldman Sachs Group Inc. (0.86%) and Renaissance Technologies LLC (0.71%). Company insiders that own Arrowhead Pharmaceuticals stock include Bruce D Given, Christopher Richard Anzalone, Douglas B Given, Kenneth Allen Myszkowski, Mauro Ferrari, Michael S Perry, Patrick O'brien, Peter Brian Leone, William D Waddill and Zhen Li. View Institutional Ownership Trends for Arrowhead Pharmaceuticals.

Which major investors are selling Arrowhead Pharmaceuticals stock?

ARWR stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Farallon Capital Management LLC, Candriam Luxembourg S.C.A., Principal Financial Group Inc., Rafferty Asset Management LLC, Goldman Sachs Group Inc., Oak Ridge Investments LLC and Fiera Capital Corp. Company insiders that have sold Arrowhead Pharmaceuticals company stock in the last year include Bruce D Given, Christopher Richard Anzalone, Douglas B Given, Kenneth Allen Myszkowski, Mauro Ferrari, Michael S Perry and Patrick O'brien. View Insider Buying and Selling for Arrowhead Pharmaceuticals.

Which major investors are buying Arrowhead Pharmaceuticals stock?

ARWR stock was purchased by a variety of institutional investors in the last quarter, including Eagle Asset Management Inc., FMR LLC, Credit Suisse AG, American International Group Inc., Mutual of America Capital Management LLC, Retirement Systems of Alabama, Man Group plc and Alliancebernstein L.P.. View Insider Buying and Selling for Arrowhead Pharmaceuticals.

How do I buy shares of Arrowhead Pharmaceuticals?

Shares of ARWR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Arrowhead Pharmaceuticals' stock price today?

One share of ARWR stock can currently be purchased for approximately $40.50.

How big of a company is Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals has a market capitalization of $4.12 billion and generates $168.80 million in revenue each year. The biotechnology company earns $67.97 million in net income (profit) each year or $0.69 on an earnings per share basis. Arrowhead Pharmaceuticals employs 116 workers across the globe.View Additional Information About Arrowhead Pharmaceuticals.

What is Arrowhead Pharmaceuticals' official website?

The official website for Arrowhead Pharmaceuticals is http://www.arrowheadpharma.com/.

How can I contact Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals' mailing address is 177 E. Colorado Blvd Suite 700, Pasadena CA, 91105. The biotechnology company can be reached via phone at 626-304-3400 or via email at [email protected]


MarketBeat Community Rating for Arrowhead Pharmaceuticals (NASDAQ ARWR)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  443 (Vote Outperform)
Underperform Votes:  415 (Vote Underperform)
Total Votes:  858
MarketBeat's community ratings are surveys of what our community members think about Arrowhead Pharmaceuticals and other stocks. Vote "Outperform" if you believe ARWR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARWR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/18/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel